168 related articles for article (PubMed ID: 38035700)
1. Network and Computational Drug Repurposing Analysis for c-Myc Inhibition in Burkitt Lymphoma.
Lee Y; Nam S
Cancer Genomics Proteomics; 2023 Dec; 20(6suppl):712-722. PubMed ID: 38035700
[TBL] [Abstract][Full Text] [Related]
2. Noncanonical regulation of the Hedgehog mediator GLI1 by c-MYC in Burkitt lymphoma.
Yoon JW; Gallant M; Lamm ML; Iannaccone S; Vieux KF; Proytcheva M; Hyjek E; Iannaccone P; Walterhouse D
Mol Cancer Res; 2013 Jun; 11(6):604-15. PubMed ID: 23525267
[TBL] [Abstract][Full Text] [Related]
3. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
[TBL] [Abstract][Full Text] [Related]
4. Deep sequencing of MYC DNA-binding sites in Burkitt lymphoma.
Seitz V; Butzhammer P; Hirsch B; Hecht J; Gütgemann I; Ehlers A; Lenze D; Oker E; Sommerfeld A; von der Wall E; König C; Zinser C; Spang R; Hummel M
PLoS One; 2011; 6(11):e26837. PubMed ID: 22102868
[TBL] [Abstract][Full Text] [Related]
5. Molecular characteristics of terminal deoxynucleotidyl transferase negative precursor B-cell phenotype Burkitt leukemia with IGH-MYC rearrangement.
Yoon J; Yun JW; Jung CW; Ju HY; Koo HH; Kim SH; Kim HJ
Genes Chromosomes Cancer; 2020 Apr; 59(4):255-260. PubMed ID: 31705772
[TBL] [Abstract][Full Text] [Related]
6. Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma.
Onnis A; De Falco G; Antonicelli G; Onorati M; Bellan C; Sherman O; Sayed S; Leoncini L
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20930934
[TBL] [Abstract][Full Text] [Related]
7. BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells.
Chen E; Pei R
J Int Med Res; 2020 May; 48(5):300060520926093. PubMed ID: 32468878
[TBL] [Abstract][Full Text] [Related]
8. Retinoic acid induces persistent, RARalpha-mediated anti-proliferative responses in Epstein-Barr virus-immortalized b lymphoblasts carrying an activated C-MYC oncogene but not in Burkitt's lymphoma cell lines.
Cariati R; Zancai P; Quaia M; Cutrona G; Giannini F; Rizzo S; Boiocchi M; Dolcetti R
Int J Cancer; 2000 May; 86(3):375-84. PubMed ID: 10760826
[TBL] [Abstract][Full Text] [Related]
9. miR‑29 promoter and enhancer methylation identified by pyrosequencing in Burkitt lymhoma cells: Interplay between MYC and miR‑29 regulation.
Mazzoccoli L; Robaina MC; Bacchi CE; Soares Lima SC; Klumb CE
Oncol Rep; 2019 Aug; 42(2):775-784. PubMed ID: 31173259
[TBL] [Abstract][Full Text] [Related]
10. Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma.
Tsagarakis NJ; Papadhimitriou SI; Pavlidis D; Liapis K; Gortzolidis G; Kostopoulos IV; Marinakis T; Paterakis G
Cytometry B Clin Cytom; 2020 Sep; 98(5):412-420. PubMed ID: 32497402
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.
Giulino-Roth L; van Besien HJ; Dalton T; Totonchy JE; Rodina A; Taldone T; Bolaender A; Erdjument-Bromage H; Sadek J; Chadburn A; Barth MJ; Dela Cruz FS; Rainey A; Kung AL; Chiosis G; Cesarman E
Mol Cancer Ther; 2017 Sep; 16(9):1779-1790. PubMed ID: 28619753
[TBL] [Abstract][Full Text] [Related]
12. Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1.
Vettraino M; Manerba M; Govoni M; Di Stefano G
Anticancer Drugs; 2013 Sep; 24(8):862-70. PubMed ID: 23797802
[TBL] [Abstract][Full Text] [Related]
13. Low incidence of MYC/BCL2 double-hit in Burkitt lymphoma.
Yoshida M; Ichikawa A; Miyoshi H; Kiyasu J; Kimura Y; Niino D; Ohshima K
Pathol Int; 2015 Sep; 65(9):486-9. PubMed ID: 26182827
[TBL] [Abstract][Full Text] [Related]
14. Pediatric B-Cell Lymphoma With Lymphoblastic Morphology, TdT Expression, MYC Rearrangement, and Features Overlapping With Burkitt Lymphoma.
Meznarich J; Miles R; Paxton CN; Afify Z
Pediatr Blood Cancer; 2016 May; 63(5):938-40. PubMed ID: 26785246
[TBL] [Abstract][Full Text] [Related]
15. Burkitt lymphoma- a rare but challenging lymphoma.
Casulo C; Friedberg JW
Best Pract Res Clin Haematol; 2018 Sep; 31(3):279-284. PubMed ID: 30213397
[TBL] [Abstract][Full Text] [Related]
16. Different Mechanisms of Regulation of the Warburg Effect in Lymphoblastoid and Burkitt Lymphoma Cells.
Mushtaq M; Darekar S; Klein G; Kashuba E
PLoS One; 2015; 10(8):e0136142. PubMed ID: 26312753
[TBL] [Abstract][Full Text] [Related]
17. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.
Carey CD; Gusenleitner D; Chapuy B; Kovach AE; Kluk MJ; Sun HH; Crossland RE; Bacon CM; Rand V; Dal Cin P; Le LP; Neuberg D; Sohani AR; Shipp MA; Monti S; Rodig SJ
J Mol Diagn; 2015 Jan; 17(1):19-30. PubMed ID: 25468432
[TBL] [Abstract][Full Text] [Related]
18. Decitabine represses translocated MYC oncogene in Burkitt lymphoma.
Guan H; Xie L; Klapproth K; Weitzer CD; Wirth T; Ushmorov A
J Pathol; 2013 Apr; 229(5):775-83. PubMed ID: 23341364
[TBL] [Abstract][Full Text] [Related]
19. Update on Burkitt Lymphoma.
Dunleavy K; Little RF; Wilson WH
Hematol Oncol Clin North Am; 2016 Dec; 30(6):1333-1343. PubMed ID: 27888884
[TBL] [Abstract][Full Text] [Related]
20. p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53.
Lindström MS; Klangby U; Wiman KG
Oncogene; 2001 Apr; 20(17):2171-7. PubMed ID: 11360201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
